Clinical Trial

Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke

Name: Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke — clinical trial record (NCT07241520)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SAIL

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-11-17.

Status change: Not Yet Recruiting → Recruiting 2026-01-03

Trial Details

NCT Number	NCT07241520
Lead Sponsor	Shanghai Hutchison Pharmaceuticals Limited Collaborators: Beijing Tiantan Hospital
Conditions	Acute Ischemic Stroke
Enrollment	1,096 participants
Start Date	2025-12-08
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-06